Unicorn India Ventures has formed a strategic agreement with US-based Continuum Fund to transfer stakes in six of its portfolio startups to the American investor for INR 50 crore.
Unicorn India’s six portfolio startups are Genrobotics, Sequretek, Clootrack, Inc42, Inntot, and NeuroEquilibrium. Unicorn’s first fund, which was established in 2015 and managed a portfolio of 18 early-stage startups, initially backed these startups. claims that its first fund returned all of its investors’ money, as well as a more than 60x partial exit from fintech startup Open Bank.
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Unicorn India Ventures has formed a strategic agreement with US-based Continuum Fund to transfer stakes in six of its portfolio startups to the American investor for INR 50 crore.
Unicorn India’s six portfolio startups are Genrobotics, Sequretek, Clootrack, Inc42, Inntot, and NeuroEquilibrium. Unicorn’s first fund, which was established in 2015 and managed a portfolio of 18 early-stage startups, initially backed these startups. claims that its first fund returned all of its investors’ money, as well as a more than 60x partial exit from fintech startup Open Bank.
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
